EC Nutrition

Akkermansia muciniphila is a gut bacterium that facilitates the reinforcement the intestinal barrier, that inhibits inflammation, and beneficially transforms glucose and lipid metabolism. We conducted a randomized, placebo-controlled trial, where 60 adults received either a probiotic containing A. muciniphila or placebo for 60 days. We measured the metabolic parameters at baseline and day 60, including fasting and post-prandial glucose, HbA1c, lipids, insulin sensitivity and secretion, body weight, BMI, waist circumference, and blood pressure. We also assessed safety through vital signs and physical examination. At day 60, the study group showed significantly lower fasting glucose (109.4 ± 14.6 vs 113.0 ± 14.9 mg/dL; p = 0.0338), post-prandial glucose (131.7 ± 25.5 vs 145.7 ± 25.4 mg/dL; p = 0.0373), HbA1c (4.78 ± 0.17 vs 5.55 ± 0.64%; p = 0.0428), and triglycerides (122.4 ± 42.4 vs 151.1 ± 54.9 mg/dL; p = 0.0272) than the placebo group, along with reductions in body weight, BMI, waist circumference, and diastolic blood pressure. No meaningful changes were detected in total, LDL, or HDL cholesterol or insulin sensitivity, and the probiotic was well tolerated without serious adverse events. Overall, 60 days of A. muciniphila supplementation appeared safe and yielded clinically relevant benefits for glycemic control, triglycerides, and anthropometric measures, supporting the need for larger and longer-term studies.

 Keywords: Akkermansia muciniphila; Nugensia™; Metabolic Health

1. Greer R., et al. “Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism”. Nature Communications 7 (2016): 13329.
2. Depommier C., et al. “Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study”. Nature Medicine 7 (2019): 1096-1103.
3. Katiraei S., et al. “Akkermansia muciniphila exerts lipid-lowering and immunomodulatory effects without affecting neointima formation in hyperlipidemic APOE*3-Leiden.CETP mice”. Molecular Nutrition and Food Research 15 (2020): e1900732.
4. Abot A., et al. “Pasteurized Akkermansia muciniphila improves glucose metabolism and is linked with increased hypothalamic nitric oxide release”. Heliyon7 (2023): 18196.
5. Yan S., et al. “Effect of Akkermansia muciniphila on pancreatic islet β-cell function in rats with prediabetes mellitus induced by a high-fat diet”. Bioresources and Bioprocessing 1 (2024): 51.
6. Zhang Y., et al. “Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: efficacy depends on its baseline levels in the gut”. Cell Metabolism 3 (2025): 592-605.e6.
7. He K., et al. “Akkermansia muciniphila: a potential target for the prevention of diabetes”. Foods1 (2025): 23.
8. Byndloss M., et al. “The gut microbiota and diabetes: research, translation, and clinical applications 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum”. Diabetes Care9 (2024): 1760-1782.
9. Yuan F., et al. “A systematic review and meta-analysis of randomized controlled trials on the effects of turmeric and curcuminoids on blood lipids in adults with metabolic diseases”. Advances in Nutrition 5 (2019): 791-802.